669 related articles for article (PubMed ID: 18021759)
41. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only.
Fride E; Feigin C; Ponde DE; Breuer A; Hanus L; Arshavsky N; Mechoulam R
Eur J Pharmacol; 2004 Dec; 506(2):179-88. PubMed ID: 15588739
[TBL] [Abstract][Full Text] [Related]
42. A study investigating the acute dose-response effects of 13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana.
Weinstein A; Brickner O; Lerman H; Greemland M; Bloch M; Lester H; Chisin R; Sarne Y; Mechoulam R; Bar-Hamburger R; Freedman N; Even-Sapir E
J Psychopharmacol; 2008 Jun; 22(4):441-51. PubMed ID: 18635724
[TBL] [Abstract][Full Text] [Related]
43. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
Wilkinson JD; Williamson EM
J Dermatol Sci; 2007 Feb; 45(2):87-92. PubMed ID: 17157480
[TBL] [Abstract][Full Text] [Related]
44. Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors.
Fride E; Ponde D; Breuer A; Hanus L
Neuropharmacology; 2005 Jun; 48(8):1117-29. PubMed ID: 15910887
[TBL] [Abstract][Full Text] [Related]
45. Pharmacology of cannabinoids.
Grotenhermen F
Neuro Endocrinol Lett; 2004; 25(1-2):14-23. PubMed ID: 15159677
[TBL] [Abstract][Full Text] [Related]
46. Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol.
Zuardi AW; Finkelfarb E; Bueno OF; Musty RE; Karniol IG
Arch Int Pharmacodyn Ther; 1981 Jan; 249(1):137-46. PubMed ID: 6261703
[TBL] [Abstract][Full Text] [Related]
47. Motor effects of delta 9 THC in cerebellar Lurcher mutant mice.
Lorivel T; Hilber P
Behav Brain Res; 2007 Aug; 181(2):248-53. PubMed ID: 17531329
[TBL] [Abstract][Full Text] [Related]
48. Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling.
Takeda S; Yamaori S; Motoya E; Matsunaga T; Kimura T; Yamamoto I; Watanabe K
Toxicology; 2008 Mar; 245(1-2):141-6. PubMed ID: 18249480
[TBL] [Abstract][Full Text] [Related]
49. [Testing the pharmacological activity of some synthetic cannabinoids in mice (author's transl)].
Ganz AJ; Waser PG
Arzneimittelforschung; 1980; 30(3):471-7. PubMed ID: 7387758
[TBL] [Abstract][Full Text] [Related]
50. Long-term consequences of a single treatment of mice with an ultra-low dose of Delta9-tetrahydrocannabinol (THC).
Amal H; Fridman-Rozevich L; Senn R; Strelnikov A; Gafni M; Keren O; Sarne Y
Behav Brain Res; 2010 Jan; 206(2):245-53. PubMed ID: 19766676
[TBL] [Abstract][Full Text] [Related]
51. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.
D'Souza DC; Abi-Saab WM; Madonick S; Forselius-Bielen K; Doersch A; Braley G; Gueorguieva R; Cooper TB; Krystal JH
Biol Psychiatry; 2005 Mar; 57(6):594-608. PubMed ID: 15780846
[TBL] [Abstract][Full Text] [Related]
52. Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures.
Moldzio R; Pacher T; Krewenka C; Kranner B; Novak J; Duvigneau JC; Rausch WD
Phytomedicine; 2012 Jun; 19(8-9):819-24. PubMed ID: 22571976
[TBL] [Abstract][Full Text] [Related]
53. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.
Curran HV; Brignell C; Fletcher S; Middleton P; Henry J
Psychopharmacology (Berl); 2002 Oct; 164(1):61-70. PubMed ID: 12373420
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological profile of delta 9-THC carbamate.
Little PJ; Kaplan NC; Martin BR
Alcohol Drug Res; 1987; 7(5-6):517-23. PubMed ID: 3040025
[TBL] [Abstract][Full Text] [Related]
55. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood.
Rubino T; Realini N; Braida D; Guidi S; Capurro V; Viganò D; Guidali C; Pinter M; Sala M; Bartesaghi R; Parolaro D
Hippocampus; 2009 Aug; 19(8):763-72. PubMed ID: 19156848
[TBL] [Abstract][Full Text] [Related]
56. The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain.
Gómez M; Hernández M; Fernández-Ruiz J
Brain Res; 2007 May; 1145():48-55. PubMed ID: 17320842
[TBL] [Abstract][Full Text] [Related]
57. Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat.
Whitlow CT; Freedland CS; Porrino LJ
Psychopharmacology (Berl); 2002 May; 161(2):129-36. PubMed ID: 11981592
[TBL] [Abstract][Full Text] [Related]
58. Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential.
Stadelmann AM; Juckel G; Arning L; Gallinat J; Epplen JT; Roser P
Neurosci Lett; 2011 May; 496(1):60-4. PubMed ID: 21513772
[TBL] [Abstract][Full Text] [Related]
59. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system.
Zarrindast MR; Sarahroodi S; Arzi A; Khodayar MJ; Taheri-Shalmani S; Rezayof A
Behav Pharmacol; 2008 Oct; 19(7):716-23. PubMed ID: 18797248
[TBL] [Abstract][Full Text] [Related]
60. Acute delta9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion.
Gorriti MA; Ferrer B; del Arco I; Bermúdez-Silva FJ; de Diego Y; Fernandez-Espejo E; Navarro M; Rodríguez de Fonseca F
Pharmacol Biochem Behav; 2005 May; 81(1):71-7. PubMed ID: 15894066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
